CN113116911A - Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine - Google Patents
Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine Download PDFInfo
- Publication number
- CN113116911A CN113116911A CN202110629962.3A CN202110629962A CN113116911A CN 113116911 A CN113116911 A CN 113116911A CN 202110629962 A CN202110629962 A CN 202110629962A CN 113116911 A CN113116911 A CN 113116911A
- Authority
- CN
- China
- Prior art keywords
- platycodin
- apiose
- liver cancer
- migration
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of apiose-removed platycodin D in preparing a medicine for resisting liver cancer cell metastasis relates to the field of anticancer medicines. The invention determines the influence of the apiose platycodin D on the cell migration capacity through a Transwell cell migration test and a scratch test, and the test proves that the apiose platycodin D can obviously inhibit the movement and migration of human hepatoma cell strains HepG-2 and MHCCLM3 and has obvious capacity of inhibiting the movement and migration of tumor cells. The apiose-removed platycodin D shows good anti-liver cancer cell transfer activity, can be used for preparing anti-liver cancer cell transfer medicines, and has good development and application prospects. Before the invention, no report on the aspect of preventing and treating tumor cell metastasis by applying apiose-removed platycodin D is available. The invention relates to application of apiose-removed platycodin D in preparing a medicine for resisting liver cancer cell metastasis, and belongs to the first disclosure.
Description
Technical Field
The invention relates to the technical field of anti-cancer drugs, in particular to application of apiose-removed platycodin D in preparation of a drug for resisting liver cancer cell metastasis.
Background
Cancer is one of the most harmful diseases to human life health, and a large number of people die of cancer every year. Tumor cell metastasis is the major cause of malignancy treatment failure and patient death, while metastasis is an essential biological feature of malignancies. Tumor cell metastasis is a multistep, multistage, multi-pathway, complex series of processes involving multigenic changes, including shedding of tumor cells from primary foci, invasion of blood or lymphatic vessels, migration, adhesion and appropriate site-induced tumor vascularization, immunity against host tumors, and ultimately the formation of distant metastases. Research shows that not only a plurality of genes are involved in the infiltration and metastasis process of tumor cells, but also the combined action and regulation of some related factors, enzymes, proteins and the like.
The apigenin-removed platycodin D is a novel saponin compound extracted from platycodon grandiflorum (Xu BJ, et al. in vitro inhibiting effect of riterpenapplying saponin from Platycodi Radix on supercritical lipase [ J ]. Archives of pharmaceutical Research,2005,28(2): 180-. At present, the disclosed applications of the apiose-removed platycodin D mainly comprise: protection against inflammatory cholestatic liver injury (Kim T-W, et al. protective effect Of the aqueous extract from the root Of plant grandiflora on cholestisis-induced fatty in microorganisms (vol 50, pg 1473,2012) [ J ]. Pharmaceutical Biology,2016,54(1): 187), Antioxidant (Jeon S-H, et al. effective Of the cosmetic Content and Antioxidant Activities Of the plant grandiflora radiation by treating Length [ J ]. Korea Journal Of medical Science, 23(5): 363), anti-Hepatitis C Virus (Kim J-W, sample J. fatty in tissue Of fatty tissue Of pancreas grandiflora [ IV. fatty in J.) (III. fatty in vitro, III. fatty tissue Of liver origin [ J.: III. fatty tissue Of liver tissue Of tissue culture [ IV ] Of fatty tissue Of tissue origin, pancreas grandiflora [ IV. fatty tissue Of liver, tissue Of tissue origin [ IV. fatty tissue Of tissue origin, tissue Of, 2005,28(2):180-185.). The application of the apiose-removed platycodin D in the anticancer field is not reported yet.
Disclosure of Invention
The invention aims to provide a new application of apiose-removed platycodin D, and particularly relates to an application of apiose-removed platycodin D in preparation of a liver cancer cell metastasis resisting medicine.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the invention discloses application of apiose-removed platycodin D in preparing a medicine for resisting liver cancer cell metastasis.
In a preferred embodiment, the concentration of the apiose-removed platycodin D is 10 to 20 μ M.
In a more preferred embodiment, the concentration of the apigenin D is 20 μ M.
In a preferred embodiment, the structural formula of the apiose platycodin D is shown as follows:
in a preferred embodiment, the apiose-removed platycodin D plays an anti-liver cancer cell transfer activity by inhibiting the migration of human liver cancer cell strains HepG-2 and MHCCLM 3.
The invention has the beneficial effects that:
the invention determines the influence of the apiose platycodin D on the cell migration capacity through a Transwell cell migration test and a scratch test, and the test proves that the apiose platycodin D can obviously inhibit the movement and migration of human hepatoma cell strains HepG-2 and MHCCLM3 and has obvious capacity of inhibiting the movement and migration of tumor cells. The apiose-removed platycodin D shows good anti-liver cancer cell transfer activity, can be used for preparing anti-liver cancer cell transfer medicines, and has good development and application prospects.
Drawings
FIG. 1 shows the results of the Transwell cell migration test in example 1 to determine the effect of apigenin-platycodin D on cell migration ability.
FIG. 2 shows the results of the Transwell cell migration test in example 1 to determine the effect of apigenin-D on cell migration ability.
FIG. 3 shows the results of the scratch test in example 2 to determine the effect of apiose platycodin D on the migration ability of cells.
FIG. 4 shows the results of the scratch test in example 2 to determine the effect of apiose platycodin D on the migration ability of cells.
Detailed Description
The invention discloses application of apiose-removed platycodin D in preparing a medicine for resisting liver cancer cell metastasis.
Preferably, the concentration of the apiose-removed platycodin D is 10-20 mu M.
More preferably, the concentration of the apiose-removed platycodin D is 20 mu M.
Preferably, the structural formula of the apiose-removed platycodin D is as follows:
preferably, the apiose-removed platycodin D plays an anti-liver cancer cell transfer activity by inhibiting the migration of human liver cancer cell strains HepG-2 and MHCCLM 3.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Material sources are as follows:
the apiose-removed platycodin D is purchased from Dorper scientific development Co.
The human hepatoma cell strain HepG-2 was purchased from Beijing Beinanna Chuanglian union Biotechnology research institute.
The human hepatoma cell strain MHCCLM3 was purchased from the institute of Biotechnology, Chuanglian union, Beijing.
Example 1Transwell cell migration assay to determine the Effect of apigenin D on the migration Capacity of cells
The method comprises the following steps: human hepatoma cell lines HepG-2 and MHCCLM3 in logarithmic growth phase were digested. Counting and adjusting cell concentration to 1X 10 with complete cell culture broth6One/ml of the cells were inoculated in a 24-well cell culture plate (i.e., 5X 10 cells/well) at 500. mu.l/well4One/well), after the cells adhere to the wall (about 24 h), the culture solution is aspirated and washed 2 times with Hank's solution. The test was divided into a blank control group and a drug-treated group. The blank control group is replaced by DMEM medium containing 10% fetal bovine serum; the drug treatment groups replaced medium containing apiose-removed platycodin D at concentrations of 10. mu.M and 20. mu.M. Culturing for 48h, preparing a new 24-well plate, adding DMEM medium containing 10% fetal calf serum into the well, placing the transwell chamber into the well for standby, digesting the cells in each experimental well and placing the cells into an EP tube, centrifuging at 3000rpm/min for 5min, discarding the supernatant, adding 200 μ L of DMEM medium without fetal calf serum into each EP tube, blowing the cells evenly and lightly, placing the cells into the transwell chamber, culturing at 37 ℃, and adding 5% CO2And incubating in an incubator for 24 h. Cells that did not migrate to the upper surface were then carefully wiped off with a cotton swab, and cells that migrated to the lower surface of the membrane were fixed with 4% paraformaldehyde and stained with crystal violet. Randomly select 3 high power lens field technique migration cell number. The experiment was repeated 3 times. The cell mobility was calculated by the following formula.
Cell mobility ═ 100% (mean value of number of cells in experimental group/mean value of number of cells in blank control group).
As a result: as shown in figure 1 and figure 2, the apiose-removed platycodin D has a dose-dependent migration inhibition effect on human hepatoma cell strains HepG-2 and MHCCLM 3. Moreover, the inhibition of the migration of MHCCLM3 cells is more obvious, and the relative percentage of migrated cells is obviously reduced compared with a blank control group (P < 0.05). The experimental data are shown in table 1.
TABLE 1Transwell method for determining the effect of apiose-removed platycodin D on cell migration of HepG-2 and MHCCLM3 (n ═ 3 x. + -.s)
| Group of | HepG-2(％) | MHCCLM3(％) |
| Blank control | 100±2.74 | 100±2.58 |
| 10μM | 50.54±2.04 | 3.30±0.10 |
| 20μM | 25.14±2.12 | 1.95±0.18 |
And (4) conclusion: the experiments prove that the apiose-removed platycodin D can obviously inhibit the migration of human liver cancer cell strains HepG-2 and MHCCLM 3. Therefore, the apiose-removed platycodin D has the activity of resisting the liver cancer cell metastasis, and can be applied to the preparation of the liver cancer cell metastasis resisting medicine.
Example 2 scratch test to examine the influence of apiose-removed platycodin D on cell migration ability
The method comprises the following steps: human hepatoma cell lines HepG-2 and MHCCLM3 in logarithmic growth phase were digested. Count and adjust cell concentration to 5X 10 with complete cell culture broth 52 ml/ml of the suspension was inoculated into 6-well cell culture plates (i.e., 1X 10 cells)6One/well), after the cells adhere to the wall (about 24 h), the culture solution is aspirated and washed 2 times with Hank's solution. The test was divided into a blank control group and a drug-treated group. The blank control group was replaced with DMEM containing 10% fetal bovine serumA group; the drug treatment group was replaced with medium containing apiose-removed platycodin D at concentrations of 10. mu.M and 20. mu.M. After 24h, the culture medium in the wells was aspirated, a linear trace was gently drawn from top to bottom on the cell layer surface using a sterile pipette tip, gently rinsed with sterile PBS, and then placed under a microscope to measure the scratch width (0 h). After 12, 24 and 48h, respectively, the culture medium in the wells was aspirated, rinsed with sterile PBS and placed under a microscope to measure the width of the scratch. The cell mobility was calculated by the following formula.
Cell mobility ═ (0h scratch width-scratch width at each time point)/0 h scratch width × 100% results: as shown in figure 2 and figure 3, the apiose-removed platycodin D has a dose-dependent migration inhibition effect on human hepatoma cell strains HepG-2 and MHCCLM 3. Moreover, the inhibition of the migration of MHCCLM3 cells is more obvious, and the relative percentage of migrated cells is obviously reduced compared with a blank control group (P < 0.05). The experimental data are shown in table 2.
Table 2 scratch assay to examine the effect of apiose-removed platycodin D on HepG-2 and MHCCLM3 cell migration (n ═ 3x ± s)
| Group of | HepG-2(％) | MHCCLM3(％) |
| Blank control | 19.25±3.54 | 25.28±4.04 |
| 10μM | 6.85±1.74 | 5.91±1.14 |
| 20μM | 5.43±1.16 | 3.94±1.79 |
And (4) conclusion: the experiments prove that the apiose-removed platycodin D can obviously inhibit the migration of human liver cancer cell strains HepG-2 and MHCCLM 3. Therefore, the apiose-removed platycodin D has the activity of resisting the liver cancer cell metastasis, and can be applied to the preparation of the liver cancer cell metastasis resisting medicine.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: it is to be understood that modifications may be made to the technical solutions described in the foregoing embodiments, or equivalents may be substituted for some of the technical features thereof, but such modifications or substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (5)
1. Application of apiose-removed platycodin D in preparing medicine for resisting liver cancer cell metastasis is provided.
2. The use as claimed in claim 1, wherein the concentration of said apigenin D is 10-20 μ M.
3. The use as claimed in claim 2, wherein the concentration of descarvose platycodin D is 20 μ Μ.
4. The use as claimed in claim 1, wherein the structural formula of the apiose platycodin D is as follows:
5. the use as claimed in claim 1, wherein the apiose-removed platycodin D exerts anti-metastatic activity against liver cancer cells by inhibiting migration of human liver cancer cell lines HepG-2 and MHCCLM 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110629962.3A CN113116911A (en) | 2021-06-07 | 2021-06-07 | Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110629962.3A CN113116911A (en) | 2021-06-07 | 2021-06-07 | Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113116911A true CN113116911A (en) | 2021-07-16 |
Family
ID=76783234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110629962.3A Pending CN113116911A (en) | 2021-06-07 | 2021-06-07 | Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113116911A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120117197A (en) * | 2011-04-14 | 2012-10-24 | 삼척시 | Immune and anticancer activities enhanced composition containing the platycodon grandiflorum fraction from the platycodon grandiflorum roots with high purity platycosides |
| CN104887692A (en) * | 2015-06-04 | 2015-09-09 | 中国农业科学院特产研究所 | Application of platycodin D to preparation of drug for treating melanoma metastasis |
| CN111394265A (en) * | 2019-12-03 | 2020-07-10 | 延边大学 | Preparation method and application of platycodin D |
| CN111394266A (en) * | 2019-12-03 | 2020-07-10 | 延边大学 | Preparation method and application of apiose-removed platycodin D |
-
2021
- 2021-06-07 CN CN202110629962.3A patent/CN113116911A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120117197A (en) * | 2011-04-14 | 2012-10-24 | 삼척시 | Immune and anticancer activities enhanced composition containing the platycodon grandiflorum fraction from the platycodon grandiflorum roots with high purity platycosides |
| CN104887692A (en) * | 2015-06-04 | 2015-09-09 | 中国农业科学院特产研究所 | Application of platycodin D to preparation of drug for treating melanoma metastasis |
| CN111394265A (en) * | 2019-12-03 | 2020-07-10 | 延边大学 | Preparation method and application of platycodin D |
| CN111394266A (en) * | 2019-12-03 | 2020-07-10 | 延边大学 | Preparation method and application of apiose-removed platycodin D |
Non-Patent Citations (2)
| Title |
|---|
| 曹俊红，等: "桔梗皂苷D对子宫内膜癌细胞凋亡和侵袭的影响", 《中国临床药理学杂志》 * |
| 杨振杰，等: "桔梗皂苷D对HCCLM3细胞迁移侵袭影响机制探讨", 《中华肿瘤防治杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brady et al. | Alteration in ganglioside pattern and synthesis in SV40-and polyoma virus-transformed mouse cell lines | |
| CN112920983B (en) | Lactobacillus plantarum capable of improving facial sensitive skin and repairing skin barrier | |
| CN112725392B (en) | Peach gum polysaccharide with high efficiency of resisting allergy and relieving itching as well as fermentation extraction method and application thereof | |
| CN111297900A (en) | Composition rich in adipose-derived stem cell exosomes and application thereof | |
| CN110305839A (en) | Mesenchymal stem cell serum-free culture medium | |
| CN106754675A (en) | A kind of fat stem cell serum free medium and its production and use | |
| CN109517872A (en) | Application of the rhodioside in protection Stem Cell Activity | |
| CN111321111A (en) | Method for promoting skin injury repair by using adipose-derived stem cell extracellular vesicles | |
| CN114621916A (en) | Application of antioxidant in improving activity of umbilical cord mesenchymal stem cells | |
| CN112094784B (en) | Lactobacillus paracasei capable of inhibiting HaCaT cell abnormal proliferation | |
| CN113116911A (en) | Application of apiose-removed platycodin D in preparation of anti-hepatoma cell transfer medicine | |
| CN113730430B (en) | Application of small molecule saussurea involucrata polysaccharide in adiponectin secretion regulation and preparation method thereof | |
| CN112791083B (en) | Application of small molecule compound in preparation of medicine for preventing and treating silkworm microparticle | |
| WO2022199453A1 (en) | Use of rhodococcus ruber product in treatment of radiation sickness | |
| CN115671136A (en) | Application of M0 or M1 type Ly6C + CX3CR1+ monocyte-derived macrophage in treating hepatic fibrosis | |
| CN115607492A (en) | Radix ceratostigmae callus extract and preparation method and application thereof | |
| CN115261273A (en) | Lactobacillus jensenii and application thereof | |
| TWI826635B (en) | Use of composition comprising monoclonal stem cell, method for preparing monoclonal stem cell and use of stem cell | |
| CN113398163B (en) | Fermentation method of Chinese herbal medicine and application of fermentation product | |
| CN113332301A (en) | Application of platycodin D2 in preparation of anti-hepatoma cell transfer medicine | |
| CN111714537B (en) | Film agent capable of relieving chest drop and atrophy and preparation method thereof | |
| CN115364116A (en) | Application of ginsenoside Rb1 in medicine for treating bile duct cancer | |
| CN117503744A (en) | Application of meclofenamic acid in preparation of medicines for treating gastric cancer | |
| CN100486594C (en) | Use of serratia marcesens bacterial vaccine for preparing drug for treating lung fibrosis | |
| Song et al. | Reparative Effects of Schizophyllum commune Oat Bran Fermentation Broth on UVB-induced Skin Inflammation via the JAK/STAT Pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210716 |
|
| RJ01 | Rejection of invention patent application after publication |